SML2860
Triptorelin acetate
≥98% (HPLC), luteinizing hormone releasing hormone (LHRH) agonist analog, powder
别名:
6-D-Tryptophan-Luteinizing Hormone-Releasing Factor acetate, [D-Trp6]-LH-RH acetate
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C64H82N18O13 · xC2H4O2
分子量:
1311.45 (free base basis)
UNSPSC代码:
12352200
NACRES:
NA.77
生化/生理作用
Synthetic LHRH agonist analog
Triptorelin acetate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.
警示用语：
Danger
危险声明
危险分类
Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
涉药品监管产品
此项目有
Successful desensitization to gonadotropin-releasing hormone analogue triptorelin acetate using a sustained-release depot preparation.
Pauline Chan Ng et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 29(6), 660-663 (2018-05-29)
Davide Meani et al.
Therapeutic advances in urology, 10(2), 51-63 (2018-02-13)
Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持